✦ LIBER ✦

Point-of-Care versus Laboratory Monitoring of Patients Receiving Different Anticoagulant Therapies

✍ Scribed by Robert A. Reiss; Curtis E. Haas; Deborah L. Griffis; Bernadette Porter; Mary Ann Tara

Book ID: 115048596
Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 62 KB
Volume: 22
Category: Article
ISSN: 0277-0008
DOI: 10.1592/phco.22.9.677.34060

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Point-of-care monitoring of anticoagulan

Point-of-care monitoring of anticoagulant therapy in paediatric patients

✍ Fiona Newall; Mary E. Bauman 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 146 KB

PCV11 POINT-OF-CARE INR MONITORING DEVIC

PCV11 POINT-OF-CARE INR MONITORING DEVICES FOR PATIENTS ON LONG-TERM ORAL ANTICOAGULATION THERAPY

✍ T Khan 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

The clinical significance of differences

The clinical significance of differences between point-of-care and laboratory INR methods in over-anticoagulated patients

✍ A.S. Lawrie; J. Hills; I. Longair; L. Green; C. Gardiner; S.J. Machin; H. Cohen 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 418 KB

031 Enoxaparin Anticoagulation Monitorin

031 Enoxaparin Anticoagulation Monitoring in the Catheterization Laboratory Using a New Point-of-Care test

✍ Johanne Silvain; Farzin Beygui; Annick Ankri; Anne Bellemain-Appaix; Ana Pena; O 📂 Article 📅 2010 🏛 Elsevier 🌐 English ⚖ 108 KB

Point-of-care monitoring of anticoagulan

Point-of-care monitoring of anticoagulant therapy by rural community pharmacists: Description of successful outcomes

✍ Shane L. Jackson; Gregory M. Peterson; Murray House; Timothy Bartlett 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

Advances in the monitoring of oral antic

Advances in the monitoring of oral anticoagulation: Point-of-care testing, patient self-monitoring, and patient self-management

✍ Katharine E. Leaning; Jack E. Ansell 📂 Article 📅 1996 🏛 Springer US 🌐 English ⚖ 748 KB

Oral anticoagulation with warfarin sodium has proven to be an effective therapy for patients at risk for thromboembolic disease, but due to its high risk/benefit ratio, many physicians are reluctant to prescribe the drug. The development of capillary whole-blood prothrombin time (PT) monitors provid